Why it matters: White House officials have warned that the initial supply of the Johnson & Johnson vaccine would be limited due to production problems, although the company said it would abide by its agreement to supply 100 million doses to the US by the end of June.
“We are confident in our plans to deliver 100 million single-dose vaccines to the United States during the first half of 2021, and we continue to work with the U.S. government to explore all options to accelerate delivery,” he said. will Nettles say.
The vaccine is generally 66 percent effective against the virus, but shows only 57 percent efficacy in a trial in South Africa, where a problematic strain, B.1.315, has spread widely. The tension has been reported in ten U.S. states.
What’s next: The Panel of the House will also hear from executives of Pfizer, Moderna, AstraZeneca and Novavax how major vaccine manufacturers are increasing production to meet the country’s vaccination requirements.
Pfizer and Moderna each promised 300 million doses this year.